The Company's a Board of Directors is composed of 9 members, including three independent directors, each serving a three-year term. Currently, two female directors serve on the Board. Directors are elected under a candidate nomination system, with the final selection made by the shareholders' meeting from the list of nominees.

The Board convenes at least once per quarter. All directors possess the professional expertise required to fulfill their duties, bringing a wide range of competencies in business management, leadership and decision-making, industry knowledge, and financial accounting. In carrying out their responsibilities, directors uphold impartiality and independence, exercising their powers in accordance with applicable laws and regulations, the Company's Articles of Incorporation, and resolutions of the shareholders' meeting. They provide guidance and consultation on operational strategies, financial planning, and the development of innovative pharmaceuticals.

Directors continue to pursue professional development throughout their tenure. The Company also maintains liability insurance for all directors in connection with the performance of their duties.

Board Diversity and Independence

Board Diversity:
Pursuant to the Company's “Rules for Election of Directors” and “Corporate Governance Best Practice Principles,” the Board’s composition follows a policy of diversity, which is disclosed on both the Company website and the Market Observation Post System. The Company’s directors come from diverse professional backgrounds and possess the knowledge, skills, and expertise necessary to perform their functions.

In accordance with the Articles of Incorporation, the Board comprises nine seats, including three independent directors. The directors collectively represent expertise in biotechnology and pharmaceuticals, human resources and labor relations, law, investment, accounting, and engineering management . Directors also participate in ongoing training to enhance their knowledge and competencies.

The Company's Board diversity objectives specify that directors should collectively cover a broad spectrum of corporate management expertise. At least three directors, including one independent director, must have a background in biotechnology or pharmaceuticals. In addition, at least two directors must have expertise in finance, accounting, or investment. The current Board composition fully meets these requirements. Female directors account for 22% of the Board, 89% of directors hold a master's degree or above (including 33% with doctoral degrees), reflecting a high level of academic and professional attainment.

Board Independence:
The Company has established three independent director seats, representing one-third of the Board. Independent directors are elected in accordance with the “Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies.” All three independent directors meet the required professional qualifications and independence criteria. Upon election, each independent director submitted a declaration of independence and provided supporting documentation confirming compliance with Paragraphs 3 and 4 of Article 26-3 of the Securities and Exchange Act. Furthermore, none of the directors are related to one another within the second degree of kinship.
 

Chairman Ming-Tsuen Chen

  • Graduated from Department of Medicine, Kaohsiung Medical University.
  • Director, Shu-Tien Urological & Ophthalmological Clinic, Shu-Tien Medical Foundation Present Employment
  • CEO, Healthcare Division, RunTai Group

DirectorBasma C. C. Cheng

  • Representative of National Development Fund., Executive Yuan
  • MD, Graduate Institute of Labor Research, National Chengchi University 
  • Deputy Director General of Department of Human Resources Development at the National Development Council

Director Lin Shih Chia

  • Representative of National Devlopment Fund., Executive Yuan
  • Institute of Health and Welfare Policy, National Yang-Ming University
  • CEO of Foundation of Medical Professionals Alliance in Taiwan
  • General Manager, TaiAn Technologies Corp

DirectorJimmy Chang, Ph.D.

  • Ph.D. of Pharmaceutics, University of Texas at Austin. USA
  • Former Executive Director at Allergan Inc.
  • Former senior researcher at Eli Lilly & Company
  • CEO of TaiMed Biologics Inc.

Director Tamon Tseng, LLM.

  • Mr. Tseng joined Ruentex Group in 1992, and is currently serving as Special Assistant to the CEO of Ruentex Industries, Ltd.
  • Mr. Tseng was called to the English Bar in 1985. He received a B.A. from the University of Cambridge, an LL.M. from University College London, and an LL.B. from National Chengchi University.

DirectorFrank Chen

  • Representative of Chang Chun Investment, Ruentex Group
  • Master degree in Business Administration from National Taiwan University
  • Vice General Manager, Investment Management and Special Assistant to Chairman of Ruentex Group

Independent DirectoChiu, Chin-Ting.

  • MBA, National Taiwan University
  • Chairman, Securities and Futures Investors Protection Center
  • Chairman, TAIWAN-CA INC.
  • Member of Mediation Committee, Securities and Futures Investors Protection Cente

Independent DirectorGwo-Fong Lin, Ph.D

  • Doctor of Philosophy in Engineering, University of Pittsburgh
  • Distinguished Professor, National Taiwan University
  • Corresponding Member, International Academy of Engineering, Russia

Independent DirectorHoward S. Lee, Ph.D.

  • PhD in Chemistry, University of Southern California, USA
  • Partner, The CID Group
  • Chairman, Easywell Biomedicals, Inc.
  • Chairman, TAHO Pharmceuticals, Ltd.
  • Chairman, Transwell Biotech CO., Ltd.